What is fatty liver or MASLD?
Fatty liver means excess fat has accumulated in liver cells. The newer term metabolic dysfunction-associated steatotic liver disease (MASLD) is used when liver fat occurs with metabolic risk such as overweight or obesity, type 2 diabetes, abnormal cholesterol, high blood pressure or related glucose abnormalities. Many patients still know the older term NAFLD.
MASLD can remain silent for years. Liver enzymes can be normal even when clinically important disease is present, and mildly abnormal enzymes do not reveal the stage by themselves.
How do I know if I have fatty liver?
Fatty liver often causes no obvious symptoms. A clinician reviews your history, medicines, alcohol intake, examination and relevant blood tests or imaging; symptoms or body shape alone cannot confirm it. If a scan already reports fatty liver, bring the report so the next question can be your risk of liver scarring and other possible causes.
Is fatty liver linked to obesity?
Yes, excess weight and insulin resistance can be connected with fatty liver, but it can also occur without obesity. When weight-related metabolic risk is present, medical weight-management care in Lahore can form part of a liver-care plan. It does not replace assessment for fibrosis or referral when liver-specific care is needed.
Who may benefit from assessment?
- fatty liver reported on ultrasound, CT or another scan;
- persistent elevation of ALT, AST or GGT;
- type 2 diabetes, obesity or metabolic syndrome with concern about liver risk;
- high triglycerides, hypertension or sleep apnoea alongside fatty liver;
- uncertainty about alcohol, medicines, viral hepatitis or another possible cause;
- a need to understand whether fibrosis testing or hepatology referral is appropriate.
The assessment should look beyond “grade 1, 2 or 3”
An ultrasound grade describes appearance, not the amount of scar tissue. The clinically important question is whether advanced fibrosis or cirrhosis may be present. History, examination and blood tests can support non-invasive scores such as FIB-4. Depending on the result and clinical setting, elastography or specialist liver assessment may be needed.
The review may also consider alcohol exposure, hepatitis screening, prescribed and non-prescribed medicines, sleep, weight trajectory, glucose, blood pressure, lipid profile and other less common causes. No single checklist suits every patient.
Treatment targets the drivers and overall risk
For many patients, the foundation is sustained improvement in weight, food quality, physical activity, sleep and control of diabetes, cholesterol and blood pressure. The aim is not a quick “liver detox.” Some people with obesity or diabetes may benefit from medicines that also improve weight and metabolic risk, but the choice depends on diagnosis, indication, contraindications, affordability and regulatory status.
When obesity treatment is clinically indicated, Dr. Fowad’s Mounjaro and tirzepatide review explains the weight evidence, safety limits and need for monitoring.
Specific medicines for steatohepatitis or fibrosis are evolving rapidly and are not suitable for everyone. Availability and approval in Pakistan must be verified at the time of care. Trial results or overseas approval should never be converted into a promise for an individual patient.
Why patients consult Dr. Fowad
Dr. Fowad’s practice is centred on obesity, diabetes, hormones and metabolic health. That combined view is useful because fatty liver frequently travels with insulin resistance, weight-related risk, dyslipidaemia and hypertension. When advanced liver disease, a procedure or hospital-level liver care is needed, referral to gastroenterology or hepatology is part of the plan.
How to choose the best fatty-liver doctor in Lahore for your needs
If you are asking “Who is the best doctor for fatty liver in Lahore?”, start with the kind of care you need. Look for a clinician who assesses fibrosis risk rather than relying only on an ultrasound grade, reviews other possible causes, treats connected metabolic risks and refers appropriately when liver-specific care is required.
Review Dr. Fowad’s qualifications and clinical focus, then discuss the appropriate consultation and location with the clinic.
Primary guidance
- NIDDK: diagnosis of fatty liver disease.
- American Association for the Study of Liver Diseases: MASLD clinical assessment and management guidance, including 2023 guidance and later updates.
- AASLD: changes from NAFLD to MASLD terminology, 2023.
This page provides general education and does not diagnose liver disease or replace individualized care. Do not stop medicines or begin an unverified supplement, injection or “detox” based on website information.